Daiichi Sankyo sweeps out Pieris drug, 5 others in a Q1 pipeline cleanup
Just a few days after lining up $57.5 million in near-term cash from a high-profile collaboration deal with AstraZeneca on its Anticalin platform, one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
